Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/92471
Título: | Native and engineered extracellular vesicles for cardiovascular therapeutics | Autor: | Abreu, Ricardo Cerqueira de Fernandes, Hugo Martins, Paula Costa Sahoo, Susmita Emanueli, Costanza Ferreira, Lino |
Data: | 1-Jun-2020 | Editora: | Nature | Projeto: | Portuguese National Funding Agency for Science, Research and Technology (fellowship to R.C.d.A. (SFRH/SFRH/BD/129317/2017) and Project Exo- Heart (POCI-01-0145- FEDER-029919) to H.F.). P.A.d.C.M. is funded by a Dutch Heart Foundation grant (NHS2015T066). P.A.d.C.M., C.E. and L.F. are members of the EEU COST Action CardioRNA CA17129. S.S. has received grants from the NIH (HL124187, HL140469, HL148786 and NYSTEM C32562GG) and Transatlantic Foundation Leducq C.E. has received funding via a British Heart Foundation (BHF) programme grant, personal Chair awards (RG/15/5/31446 and CH/15/1/31199) and the BHF Centre of Vascular Regeneration L.F. is supported by Program Interreg Atlantic Space through the European Fund for Regional Development (Project NeuroAtlantic (EAPA_791/2018) and Pro ject 2IQBIONEURO (0624_2IQBIONEURO_6_E)) and EC Project ERAatUC (669088). |
Título da revista, periódico, livro ou evento: | Nature Reviews Cardiology | Volume: | 17 | Resumo: | Extracellular vesicles (EVs) are a heterogeneous group of natural particles that are relevant to the treatment of cardiovascular diseases. These endogenous vesicles have certain properties that allow them to survive in the extracellular space, bypass biological barriers and deliver their biologically active molecular cargo to recipient cells. Moreover, EVs can be bioengineered to increase their stability, bioactivity, presentation to acceptor cells and capacity for on-target binding at both cell-type-specific and tissue-specific levels. Bioengineering of EVs involves the modification of the donor cell before EV isolation or direct modification of the EV properties after isolation. The therapeutic potential of native EVs and bioengineered EVs has been only minimally explored in the context of cardiovascular diseases. Efforts to harness the therapeutic potential of EVs will require innovative approaches and a comprehensive integration of knowledge gathered from decades of research into molecular-compound delivery. In this Review, we outline the endogenous properties of EVs that make them natural delivery agents as well as the features that can be improved by bioengineering. We also discuss the therapeutic applications of native and bioengineered EVs to cardiovascular diseases and examine the opportunities and challenges that need to be addressed to advance this research area, with an emphasis on clinical translation. | URI: | https://hdl.handle.net/10316/92471 | DOI: | 10.1038/s41569-020-0389-5 | Direitos: | openAccess |
Aparece nas coleções: | I&D CNC - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Abreu et al., Nat Reviews Cardiology.pdf | 429.17 kB | Adobe PDF | Ver/Abrir |
Citações SCOPUSTM
99
Visto em 17/nov/2022
Citações WEB OF SCIENCETM
137
Visto em 2/mai/2023
Visualizações de página
299
Visto em 17/abr/2024
Downloads
856
Visto em 17/abr/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.